Associação entre Imunoterapia Biológica para Psoríase e Tempo para Artrite Inflamatória Incidente: Um estudo de coorte retrospectivo
Lancet Rheumatol 2023;5:200–207 doi https://doi.org/10.1016/S2665-9913(23)00034-6
Retrospective cohort study found 15 501 PsO patients in the TriNetX database during January 2014–June 2022 that were prescribed bDMARDS, of which 6.3% developed inflammatory arthritis. 3.5% of all patients in the study specifically developed PsA.
Analyses showed a significantly lower risk of PsA in PsO patients treated with IL-12/23i compared to TNFi. For inflammatory arthritis, risk of progression was significantly lower in patients prescribed IL-12/23i or IL-23i than those with TNFi. Patients prescribed with IL-17i saw no significant difference in risk compared to TNFi.
